All posts from in,

Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders Vote For Perrigo Transaction Proposal

HERTFORDSHIRE, England and PITTSBURGH, Aug. 12, 2015 /PRNewswire/ -- Mylan N.V. (MYL) today announced that Egan-Jones, one of the leading U.S. proxy advisory firms, has published a report recommending that Mylan shareholders support Mylan's proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE). Glass Lewis, another leading U.S. proxy advisory firm, also published a report today recommending that Mylan shareholders support Mylan's proposed acquisition of Perrigo.

In its recommendation Egan-Jones highlighted:

  • The experience and prior success of Mylan's management team in integrating large acquisitions into Mylan's existing businesses,
  • The shared culture between Mylan and Perrigo of integrity, respect and responsibility and that their common focus on innovation, reliability and customer service will be key contributors to a successful integration.

Mylan's Executive Chairman Robert J. Coury commented, "We are pleased with Egan-Jones' recommendation in favor of the Perrigo transaction as it serves as further affirmation of the sound strategic and financial rationale behind this combination. We are confident that this transaction will create compelling value for both Mylan and Perrigo shareholders and other stakeholders, and that our shareholders will vote in favor of this combination to create a one-of-a-kind global healthcare company."

Mylan urges its shareholders to vote "FOR" the proposal to approve the Perrigo transaction described further in its definitive proxy statement that has been filed with the SEC. Mylan intends to launch its offer to acquire Perrigo's ordinary shares after it receives the approval of Mylan shareholders at the upcoming extraordinary general meeting.


Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at


This communication contains "forward-looking statements." Such forward-looking statements may include, without limitation, statements about the proposed acquisition of Perrigo Company plc ("Perrigo") by Mylan N.V. ("Mylan") (the "Perrigo Proposal"), Mylan's acquisition (the "EPD Transaction") of Mylan Inc. and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business (the "EPD Business"), the benefits and synergies of the Perrigo Proposal or EPD Transaction, future opportunities for Mylan, Perrigo, or the combined company and products, and any other statements regarding Mylan's, Perrigo's, or the combined company's future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods. These may often be identified by the use of words such as "will," "may," "could," "should," "would," "project," "believe," "anticipate," "expect," "plan," "estimate," "forecast," "potential," "intend," "continue," "target" and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: uncertainties related to the Perrigo Proposal, including as to the timing of the offer and compulsory acquisition, whether Perrigo will cooperate with Mylan and whether Mylan will be able to consummate the offer and compulsory acquisition, whether Mylan shareholders will provide the requisite approvals for the Perrigo Proposal, the possibility that competing offers will be made, the possibility that the conditions to the consummation of the offer will not be satisfied, and the possibility that Mylan will be unable to obtain regulatory approvals for the offer and compulsory acquisition or be required, as a condition to obtaining regulatory approvals, to accept conditions that could reduce the anticipated benefits of the offer and compulsory acquisition; the ability to meet expectations regarding the accounting and tax treatments of a transaction relating to the Perrigo Proposal and the EPD Transaction; changes in relevant tax and other laws, including but not limited to changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the integration of Perrigo and the EPD Business being more difficult, time-consuming, or costly than expected; operating costs, customer loss, and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients, or...